Baseline clinical characteristics for patients with hyperdiploidy (n = 499) from the Myeloma IX clinical trial and univariate analysis of the effect on OS
| Patient characteristics . | Frequency . | Median OS, mo (95% CI) . | Univariate analysis (P) . |
|---|---|---|---|
| Sex (n = 499) | |||
| Male | 326 (65%) | 52.5 (45.3, 59.7) | .029 |
| Female | 173 (35%) | 44.7 (34.1, 55.3) | |
| Age (n = 499) | |||
| <70 | 335 (75%) | 62.1 (53.7, 70.5) | <.001 |
| ≥70 | 164 (25%) | 35.1 (30.3, 39.9) | |
| Pathway (n = 499) | |||
| Intensive | 286 (57%) | 69.8 (56.3, 83.3) | <.001 |
| Nonintensive | 213 (43%) | 34.9 (30.5, 39.3) | |
| Chemotherapy (n = 499) | |||
| Thalidomide based (CTD/CTDa) | 247 (49%) | 54.4 (44.2, 64.6) | .017 |
| Traditional (CVAD/MP) | 252 (51%) | 43.7 (36.9, 50.5) | |
| ISS (n = 362)* | |||
| I | 76 (21%) | NR | <.001 |
| II/III | 286 (79%) | 44.7 (39.7, 49.7) | |
| Bone disease (n = 494)† | |||
| Present | 357 (72%) | 48.1 (41.6, 54.6) | NS |
| Absent | 137 (28%) | 54.0 (45.3, 62.7) | |
| Coexistent adverse cytogenetics (n = 499) | |||
| Present | 195 (39%) | 35.7 (27.3, 44.1) | <.001 |
| Absent | 304 (61%) | 60.9 (53.5, 68.3) |
| Patient characteristics . | Frequency . | Median OS, mo (95% CI) . | Univariate analysis (P) . |
|---|---|---|---|
| Sex (n = 499) | |||
| Male | 326 (65%) | 52.5 (45.3, 59.7) | .029 |
| Female | 173 (35%) | 44.7 (34.1, 55.3) | |
| Age (n = 499) | |||
| <70 | 335 (75%) | 62.1 (53.7, 70.5) | <.001 |
| ≥70 | 164 (25%) | 35.1 (30.3, 39.9) | |
| Pathway (n = 499) | |||
| Intensive | 286 (57%) | 69.8 (56.3, 83.3) | <.001 |
| Nonintensive | 213 (43%) | 34.9 (30.5, 39.3) | |
| Chemotherapy (n = 499) | |||
| Thalidomide based (CTD/CTDa) | 247 (49%) | 54.4 (44.2, 64.6) | .017 |
| Traditional (CVAD/MP) | 252 (51%) | 43.7 (36.9, 50.5) | |
| ISS (n = 362)* | |||
| I | 76 (21%) | NR | <.001 |
| II/III | 286 (79%) | 44.7 (39.7, 49.7) | |
| Bone disease (n = 494)† | |||
| Present | 357 (72%) | 48.1 (41.6, 54.6) | NS |
| Absent | 137 (28%) | 54.0 (45.3, 62.7) | |
| Coexistent adverse cytogenetics (n = 499) | |||
| Present | 195 (39%) | 35.7 (27.3, 44.1) | <.001 |
| Absent | 304 (61%) | 60.9 (53.5, 68.3) |
Bold values represent significant P values.
CI, confidence interval; CTD, cyclophosphamide, thalidomide, and dexamethasone; CTDa, as CTD with attenuated dosing; CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; MP, melphalan and prednisolone; NR, not reached; NS, nonsignificant.
Missing data (n = 137).
Missing data (n = 5).